Dainippon Sumitomo Pharma

Dainippon Sumitomo Pharma and Intercept Pharmaceuticals partner

Friday, April 1, 2011

Japan-based Dainippon Sumitomo Pharma (DSP) and U.S.-based Intercept Pharmaceuticals announced an exclusive licensing agreement for the development and commercialization of Intercept’s first-in-class FXR agonist obeticholic acid (OCA, also known as INT-747), according to FierceBiotech. DSP will advance OCA in Japan and China for the treatment of chronic liver diseases, initially focusing on primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH).

[Read More]